Cases & Deals

Share

Inotrem raises €44 million in Series B round

February 2020

Client(s) Inotrem SA

Jones Day advised Inotrem SA, a French biotech company specialized in immunotherapy for acute and chronic inflammatory syndromes, in connection with its €44 million Series B round of financing led by Morningside Ventures.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.